FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
PR Newswire
INDIANAPOLIS, Aug. 28, 2026
View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.htmlSOURCE Eli Lilly and Company
The FDA has approved tirzepatide for reduction of cardiovascular risk in adults with type 2 diabetes, Eli Lilly…
The diabetes drug, already the top-prescribed branded type 2 diabetes medicine in the U.S., showed an 8% lower rate of major…
The new indication for Eli Lilly's drug is for people with Type 2 diabetes.
Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type 2…
Heart disease is is the leading cause of death for people with Type 2 diabetes
The U.S. FDA on Friday approved the use of Eli Lilly's Mounjaro to reduce the chances of heart attack or stroke in high-risk…
Mounjaro approved to reduce cardiovascular events in adults with diabetes
FDA approves Mounjaro to lower heart attack and stroke risk
Mounjaro Is Now Approved to Lower the Risk of Heart Events
Eli Lilly diabetes drug wins FDA approval to lower cardiovascular risks
Weight-loss drugs could help treat other health conditions. Here’s what could be next
Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients
Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug
Regulador dos EUA aprova Mounjaro, da Eli Lilly, para reduzir risco cardiovascular
